Scott Douglas Christensen, M.D.

Education

M.D., UC Davis, Davis CA 1991

B.S., UC Davis, Davis CA 1987

Internship: Internal Medicine, UC Davis, Davis CA 1991-1992

Residency

Internal Medicine, UC Davis, Davis CA 1992-1995

Fellowships

Hematology/Oncology, UC Davis Medical Center, Sacramento CA 1995-1998

Board Certifications

American Board of Internal Medicine,

American Board of Internal Medicine, Hematology and Oncology,

American Board of Internal Medicine, Medical Oncology, 2011

Honors and Awards

Award for "Bioethics Consultation" service provided to the the UC Davis Health Medical Staff Office, UC Davis Comprehensive Cancer Center, 2017

Honored for Expanding the WeCARE! Blood Cancer Peer Navigator Program into Cancer Care Network, UC Davis Comprehensive Cancer Center, 2015

Chief Resident, Department of Internal Medicine, UC Davis Medical Center, 1994, 1995

Alpha Omega Alpha, UC Davis, 1992

Select Recent Publications

For a comprehensive list of Dr. Christensen's publications, please click here (opens new window).

Eroglu Z, Tawbi HA, Hu J, Guan M, Frankel PH, Ruel NH, Wilczynski S, Christensen S, Gandara DR, Chow WA. A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas. Br J Cancer. 2015 May 12;112(10):1644-51. doi:10.1038/bjc.2015.126. Epub 2015 Apr 21.

Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series. J Am Acad Dermatol. 2015 Oct;73(4):645-54. doi:10.1016/j.jaad.2015.06.060. Epub 2015 Aug 7.

Canter RJ, Borys D, Olusanya A, Li CS, Lee LY, Boutin RD, Christensen SD, Tamurian RM, Monjazeb AM. Phase I Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients with Locally Advanced Soft Tissue Sarcoma of the Extremity. Ann Surg Oncol. 2014 May;21(5):1616-1623. Published online 2014 Feb 20. doi:10.1245/s10434-014-3543-7.

Gadgeel SM, Lew DL, Synold TW, LoRusso P, Chung V, Christensen SD, Smith DC, Kingsbury L, Hoering A, Kurzrock R. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother Pharmacol. 2013 Nov;72(5):1089-96. doi:10.1007/s00280-013-2297-4. Epub 2013 Sep 22.

Wasif N, Smith CA, Tamurian RM, Christensen SD, Monjazeb AM, Martinez SR, Canter RJ. Influence of physician specialty on treatment recommendations in the multidisciplinary management of soft tissue sarcoma of the extremities. JAMA Surg. 2013 Jul;148(7):632-9. doi:10.1001/jamasurg.2013.113.

Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T, Mack PC, Lara PN, Gandara DR. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Invest New Drugs. 2012 Apr;30(3):741-8. doi:10.1007/s10637-010-9562-8. Epub 2010 Oct 22.

Heifetz LJ, Christensen SD, Devere-White RW, Meyers FJ. A model for rural oncology. J Oncol Pract. 2011 May;7(3):168-71. doi:10.1200/JOP.2010.000167.

Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR. Phase I Study of Two Different Schedules of Bortezomib and Pemetrexed in Advanced Solid Tumors with Emphasis on Non-small Cell Lung Cancer. J Thoracic Oncol. 2007 Dec;2(12):1112-1116. doi:10.1097/JTO.0b013e31815ba7d0.

Meyers FJ, Linder J, Beckett L, Christensen S, Blais J, Gandara DR. Simultaneous Care: A Model Approach to the Perceived Conflict Between Investigational Therapy and Palliative Care. J Pain Symptom Manage. 2004 Dec;28(6):548-556. doi:10.1016/j.jpainsymman.2004.03.002.

Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'Donnell RT, Richman CM, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. An evaluation of barriers to accrual in the era of legislation requiring coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct;10(5):294-300. doi:10.1097/00130404-200409000-00006.